Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Launched by XVIVO PERFUSION · Jun 2, 2011
Trial Information
Current as of May 22, 2025
Unknown status
Keywords
ClinConnect Summary
These lungs will be brought to the study transplant center to be re-assessed by the transplant team. The lungs will be physiologically assessed during ex vivo perfusion with Steen Solution. Perfusion of these lungs will be performed using Steen solution with the addition of methylprednisolone, heparin and antibiotics. With respect to the decision of lung utilization those organs with a delta pO2 (Δ pO2 = Pulmonary vein pO2 - pulmonary artery pO2) during ex vivo perfusion assessment \> 350mmHg, good lung compliance, and a favorable opinion of the transplant surgeon will be considered transpl...
Gender
ALL
Eligibility criteria
- • Recipient Inclusion/Exclusion Criteria The recipient inclusion/exclusion criteria apply to patients enrolled in the control or EVLP treatment arms.
- • 1. Recipient Inclusion Criteria
- • 1. Requires single or bilateral lung transplant.
- • 2. Male or Female, 18 years of age or older.
- • 3. Subject or Subject's Representative provides a legally effective informed consent.
- • 2. Recipient exclusion Criteria
- • 1. A recipient is HIV positive.
- • 2. A recipient has active Hepatitis.
- • 3. Investigator believes that the recipient has infection that excludes them from transplant in the study.
- • 4. To receive multi-organ transplant.
- • 5. Is on hemodialysis or has chronic severe renal dysfunction. Severe renal dysfunction is defined as a glomerular filtration rate of 29 or less (mL/min/1.73m2).
- • 6. Is to have planned concurrent cardiac procedures.
- • 7. A recipient is a re-transplant. (A re-transplant is defined as a recipient having the removal and transplant of a previously transplanted lung. A recipient with a previously single lung transplant is eligible to enroll in the trial if it is for the other lung and within 6 months of previous transplant.)
- • 8. A recipient is on Nova Lung, ECMO, or on mechanical ventilation. (CPAP and BIPAP are not exclusionary)
- • Donor Inclusion/Exclusion Criteria for EVLP Assessment
- • 1. Donor Inclusion Criteria
- 1. The Donor lung must meet the following criteria to proceed with EVLP:
- 2. At the time of the clinical evaluation , the PaO2/FiO2 ≤ 300mmHg Or If PaO2/FiO2 \> 30mmHg and the donor has any one or more of the following donor risk factors:
- • Multiple blood transfusions.
- • Pulmonary edema detected via CXR, bronchoscopy or palpation of lungs.
- • Donation after circulatory death donors.
- • Investigator evaluation of donor lung as "unsuitable" for standard criteria for lung transplant. List reason for "unsuitable" determination.
- • 2. Donor Exclusion Criteria
- • 1. Lung has significant pneumonia and/or persistent purulent secretions on bronchoscopy as determined by investigator.
- • 2. Donor has known significant aspiration of gastric contents within the lung.
- • 3. Donor lung has significant mechanical lung injury or trauma determined by chest x-ray, bronchoscopy, CT Scan or visual inspection.
- • 4. Donor lung has active infectious disease such as HIV, Hepatitis B or C, HTLV or Syphilis. Note: This information is not available at the start of EVLP. Therefore this criteria can be assessed during or post EVLP, but prior to transplant.
- • Donor Inclusion/Exclusion Criteria for Transplant Suitability after EVLP
- • 1. Donor Inclusion Criteria for Transplant Suitability
- • 1. Surgeon must be clinically satisfied with the lung evaluation (i.e.) overall improvement, if not, the reason for refusal must be listed.
- • 2. Stability or improvement of other lung function parameters during EVLP perfusion - PVR, Compliance, Airway Pressures.
- 3. Two delta PO2 greater than 350 mmHg, if two delta PO2 mm Hg are not met than three out of four of the following parameters must be present:
- • One delta PO2 of \> 350 or absolute PO2 of \> 400.
- • Chest x-ray findings with absence or improvement of pulmonary edema/infiltrates
- • Compliance static (greater than 35 single and greater than 60 for a double)
- • Absence of consolidation by palpation
- • 2. Donor Exclusion Criteria for Transplant Suitability after EVLP
- • 1. All delta PO2 (s) are less than 350 mmHg (measured with a FiO2 set at 1.0) or all absolute PO2s are less than 400.
- • 2. Overall greater than 10-15% Functional deterioration of other lung function across all parameters (PVR, Compliance, PawP) with chest x-ray findings showing deterioration.
- • 3. Donor lung positive for infectious diseases such as HIV, Hepatitis B or C, or Syphilis.
- • Note: This information is not available until at the start of EVLP. Therefore this criteria can be assessed during or post EVLP, but prior to transplant.
About Xvivo Perfusion
XVIVO Perfusion is a pioneering medical technology company dedicated to advancing organ preservation and transplantation. With a focus on innovative perfusion solutions, the company develops cutting-edge systems that optimize organ viability and enhance transplant outcomes. XVIVO Perfusion's commitment to research and development drives its efforts to improve the overall success rates of organ transplants, ultimately benefiting patients in need of life-saving procedures. By collaborating with healthcare providers and academic institutions, XVIVO Perfusion aims to transform the landscape of transplantation through its state-of-the-art technologies and clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Pittsburgh, Pennsylvania, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Boston, Massachusetts, United States
Baltimore, Maryland, United States
Los Angeles, California, United States
Durham, North Carolina, United States
Seattle, Washington, United States
Aurora, Colorado, United States
Tampa, Florida, United States
Dallas, Texas, United States
Gainesville, Florida, United States
Saint Louis, Missouri, United States
Detroit, Michigan, United States
Indianapolis, Indiana, United States
Philadelphia, Pennsylvania, United States
Saint Louis, Missouri, United States
Chicago, Illinois, United States
New York, New York, United States
Patients applied
Trial Officials
Jaya Tiwari, BS, CCRP
Study Director
XVIVO Perfusion, Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials